콘텐츠로 건너뛰기
Merck
  • Treatment of a tongue lymphangioma with sirolimus after failure of surgical resection and propranolol.

Treatment of a tongue lymphangioma with sirolimus after failure of surgical resection and propranolol.

Pediatric blood & cancer (2013-11-23)
Canan Akyüz, Erman Ataş, Ali Varan
초록

Lymphangiomas of the tongue are rare, and their treatment is problematic. A 10 year-old patient with tongue lymphangioma who was previously treated with surgery and propranolol with no response was treated with sirolimus in our department. We used sirolimus with a dose of 1.6 mg/m(2)/day. After 3 months of treatment, the mass had decreased by more than 60%. We continued the treatment for 1 year with a maximum response of 70% decrease in mass. Disease remained stable 6 months after stopping therapy, the latest time of follow-up. Sirolimus appears to be effective in lymphangioma but requires further study.

MATERIALS
제품 번호
브랜드
제품 설명

USP
Propranolol hydrochloride, United States Pharmacopeia (USP) Reference Standard
Propranolol hydrochloride, European Pharmacopoeia (EP) Reference Standard
Supelco
Propranolol hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
(±)-Propranolol hydrochloride, analytical standard
Supelco
Propranolol hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
(±)-Propranolol hydrochloride, ≥99% (TLC), powder